CN116270551A - 通过盐至中性药物原位转化的组合物、透皮贴剂及应用 - Google Patents

通过盐至中性药物原位转化的组合物、透皮贴剂及应用 Download PDF

Info

Publication number
CN116270551A
CN116270551A CN202211676624.6A CN202211676624A CN116270551A CN 116270551 A CN116270551 A CN 116270551A CN 202211676624 A CN202211676624 A CN 202211676624A CN 116270551 A CN116270551 A CN 116270551A
Authority
CN
China
Prior art keywords
weight
active agent
drug
composition
proton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211676624.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·S·李
A·K·简恩
P·辛格
A·萨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corian Co ltd
Original Assignee
Corian Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corian Co ltd filed Critical Corian Co ltd
Publication of CN116270551A publication Critical patent/CN116270551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211676624.6A 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用 Pending CN116270551A (zh)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201662367502P 2016-07-27 2016-07-27
US201662367542P 2016-07-27 2016-07-27
US62/367,502 2016-07-27
US62/367,542 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US62/423,133 2016-11-16
US201762444745P 2017-01-10 2017-01-10
US201762444763P 2017-01-10 2017-01-10
US62/444,745 2017-01-10
US62/444,763 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US62/457,794 2017-02-10
US201762504408P 2017-05-10 2017-05-10
US201762504391P 2017-05-10 2017-05-10
US62/504,391 2017-05-10
US62/504,408 2017-05-10
PCT/US2017/044048 WO2018022815A2 (en) 2016-07-27 2017-07-26 Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
CN201780059417.7A CN109789105B (zh) 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780059417.7A Division CN109789105B (zh) 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用

Publications (1)

Publication Number Publication Date
CN116270551A true CN116270551A (zh) 2023-06-23

Family

ID=59523314

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201780059393.5A Pending CN109789133A (zh) 2016-07-27 2017-07-26 多奈哌齐透皮递送系统
CN201780059417.7A Active CN109789105B (zh) 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
CN201780059437.4A Active CN109789106B (zh) 2016-07-27 2017-07-26 碳酸氢钠原位转化驱动胺药物的透皮递送
CN202310658352.5A Pending CN116966166A (zh) 2016-07-27 2017-07-26 碳酸氢钠原位转化驱动胺药物的透皮递送
CN202211676624.6A Pending CN116270551A (zh) 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN201780059393.5A Pending CN109789133A (zh) 2016-07-27 2017-07-26 多奈哌齐透皮递送系统
CN201780059417.7A Active CN109789105B (zh) 2016-07-27 2017-07-26 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
CN201780059437.4A Active CN109789106B (zh) 2016-07-27 2017-07-26 碳酸氢钠原位转化驱动胺药物的透皮递送
CN202310658352.5A Pending CN116966166A (zh) 2016-07-27 2017-07-26 碳酸氢钠原位转化驱动胺药物的透皮递送

Country Status (10)

Country Link
US (13) US9993466B2 (enExample)
EP (3) EP3490558A1 (enExample)
JP (6) JP7071330B2 (enExample)
KR (9) KR102555208B1 (enExample)
CN (5) CN109789133A (enExample)
AU (7) AU2017302306A1 (enExample)
CA (3) CA3032044C (enExample)
MX (2) MX394249B (enExample)
SG (1) SG11201900692WA (enExample)
WO (3) WO2018022817A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015371308A1 (en) 2014-12-23 2017-08-03 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
AU2016355920B2 (en) * 2015-11-18 2020-11-12 Commonwealth Scientific And Industrial Research Organisation Rice grain with thickened aleurone
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CA3028436A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
US9993466B2 (en) 2016-07-27 2018-06-12 Corium International, Inc. Donepezil transdermal delivery system
CN111132669A (zh) * 2017-07-26 2020-05-08 考里安公司 具有带溶剂填充孔的微孔膜的透皮递送系统
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
BR112022007369A2 (pt) * 2019-10-24 2022-07-05 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico para a administração transdérmica de fingolimode
EP4066829A4 (en) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. Method for improving holding power of adhesive agent layer in ropinirole-containing transdermal patch, and ropinirole-containing transdermal patch having improved holding power
WO2021127092A1 (en) * 2019-12-18 2021-06-24 Pioneer Hi-Bred International, Inc. Compositions and methods for improving grain yield in plants
CN115397402A (zh) * 2020-04-14 2022-11-25 格兰尼斯制药公司 包含羟氯喹和/或氯喹的经皮和/或局部递送系统
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
MX2024000435A (es) * 2021-07-08 2024-01-29 Monsanto Technology Llc Proteinas inhibidoras de insectos novedosas.
WO2025103446A1 (zh) * 2023-11-16 2025-05-22 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259028A1 (en) * 2006-05-08 2007-11-08 Takeshi Ito Percutaneous absorption preparations of antidementia drugs
CN101568340A (zh) * 2006-12-01 2009-10-28 日东电工株式会社 经皮吸收制剂
US20120245537A1 (en) * 2008-03-11 2012-09-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system having stabilized membrane

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (enExample) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
CH603545A5 (enExample) 1972-04-20 1978-08-31 Merz & Co
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
ATE111351T1 (de) 1990-07-23 1994-09-15 Alza Corp Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin.
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
AU2266995A (en) 1994-04-21 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
JP4102901B2 (ja) 1994-09-14 2008-06-18 スリーエム カンパニー 経皮薬剤導入用マトリックス
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CN1170360A (zh) 1994-12-21 1998-01-14 瑟垃技术有限公司 具有粘性贴面和剥离密封圆片的经皮输送系统
WO1996040087A2 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
ATE229817T1 (de) 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
JP4057418B2 (ja) * 2000-11-07 2008-03-05 久光製薬株式会社 経皮吸収型製剤
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
EP1390085B1 (en) 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Hydrogel compositions
US7250394B2 (en) 2001-08-20 2007-07-31 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
JP2005501883A (ja) 2001-09-04 2005-01-20 トロムスドルフ ゲーエムベーハー ウント コンパニー カーゲー アルツナイミッテル セルタコナゾールを含む爪の機能障害および疾患の治療用の膏薬
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
US7273619B2 (en) 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
CN1870984A (zh) 2003-10-22 2006-11-29 莫茨药物股份两合公司 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
US20050149049A1 (en) 2003-10-23 2005-07-07 Assell Robert L. Exchange system for soft tissue access pathway
EP1952824A1 (en) 2003-11-21 2008-08-06 Memory Pharmaceuticals Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1715853A4 (en) 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
JPWO2005115355A1 (ja) 2004-05-28 2008-03-27 久光製薬株式会社 貼付製剤
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
MX2007004315A (es) 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7462743B2 (en) 2005-01-11 2008-12-09 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
JP5084496B2 (ja) * 2005-02-04 2012-11-28 久光製薬株式会社 経皮吸収貼付剤
US20060188558A1 (en) 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
EP2001671B1 (en) * 2006-03-28 2010-05-19 Amcor Flexibles Transpac B.V.B.A. A multilayer film free of halogens which is impermeable to aroma compounds
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
JP5097359B2 (ja) 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
TW200815045A (en) 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
BRPI0719351A2 (pt) 2006-12-01 2014-01-07 Nitto Denko Corp Preparação adesiva estabilizada contendo donezepil
KR101408488B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
BRPI0814697B8 (pt) 2007-07-10 2021-05-25 Agile Therapeutics Inc dispositivo de liberação de fármacos
US9017301B2 (en) 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (es) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
AU2010204986B2 (en) * 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
KR101325104B1 (ko) 2009-09-16 2013-11-07 주식회사 삼양바이오팜 경피 투여 제형 및 그 제조 방법
ES2652491T3 (es) 2009-10-21 2018-02-02 Teikoku Seiyaku Co., Ltd. Preparación que contiene donepecilo de absorción transdérmica
CN102048678A (zh) 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
PT2519225E (pt) 2009-12-30 2015-07-27 Novartis Ag Tiras finas de nicotina extrudidas por fusão
US20100178307A1 (en) 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
US9370495B2 (en) 2010-02-24 2016-06-21 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
JP5665861B2 (ja) 2010-04-28 2015-02-04 久光製薬株式会社 ドネペジル含有経皮吸収製剤
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
EP3434257A1 (en) 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
US9844515B2 (en) 2010-11-17 2017-12-19 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
EA201390980A1 (ru) * 2010-12-29 2013-11-29 Фармафилм С.Р.Л. Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония
TWI433904B (zh) * 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (ja) 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
WO2015031552A1 (en) * 2013-08-30 2015-03-05 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
EP3054933A4 (en) * 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
CN105722502A (zh) 2013-11-17 2016-06-29 株式会社梅德瑞科思 经皮吸收胶体型液体制剂
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
CA2951706A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
CA2955241C (en) * 2014-07-18 2023-03-28 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
CN107106510A (zh) 2014-12-18 2017-08-29 Icure药品株式会社 含有多奈哌齐为有效成分的经皮吸收制剂
WO2016122806A1 (en) 2015-01-28 2016-08-04 Dnx Biotech, Llc Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
EP3310348B1 (en) 2015-06-22 2020-08-05 Corium, Inc. Transdermal adhesive composition comprising a poorly soluble therapeutic agent
JP6462880B2 (ja) * 2015-07-27 2019-01-30 久光製薬株式会社 アセナピン含有貼付剤の製造方法
US10966936B2 (en) * 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CN105693556A (zh) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
CA3028436A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
US9993466B2 (en) 2016-07-27 2018-06-12 Corium International, Inc. Donepezil transdermal delivery system
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
CN111132669A (zh) * 2017-07-26 2020-05-08 考里安公司 具有带溶剂填充孔的微孔膜的透皮递送系统

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259028A1 (en) * 2006-05-08 2007-11-08 Takeshi Ito Percutaneous absorption preparations of antidementia drugs
CN101460156A (zh) * 2006-05-08 2009-06-17 帝国制药株式会社 抗痴呆药的经皮吸收制剂
CN101568340A (zh) * 2006-12-01 2009-10-28 日东电工株式会社 经皮吸收制剂
CN101605545A (zh) * 2006-12-01 2009-12-16 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
US20120245537A1 (en) * 2008-03-11 2012-09-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system having stabilized membrane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨解人等: "《护理药理学》", vol. 1, 31 January 2010, 军事医学科学出版社, pages: 84 *
郭涛主编: "《新编药物动力学》", vol. 1, 31 January 2005, 中国科学技术出版社, pages: 344 *

Also Published As

Publication number Publication date
AU2023203618B2 (en) 2025-09-18
EP3490540A1 (en) 2019-06-05
AU2023203616A1 (en) 2023-07-06
KR102545649B1 (ko) 2023-06-22
JP2019523270A (ja) 2019-08-22
CN109789106B (zh) 2023-06-27
KR102545643B1 (ko) 2023-06-21
KR20230098349A (ko) 2023-07-03
JP2022140751A (ja) 2022-09-27
KR20230097203A (ko) 2023-06-30
JP7153010B2 (ja) 2022-10-13
WO2018022815A3 (en) 2018-03-08
AU2025205205A1 (en) 2025-07-24
CN109789133A (zh) 2019-05-21
EP3490541B1 (en) 2025-07-09
US20180028663A1 (en) 2018-02-01
EP3490541A2 (en) 2019-06-05
US20180235901A1 (en) 2018-08-23
WO2018022817A1 (en) 2018-02-01
AU2017302306A1 (en) 2019-02-14
US20250375396A1 (en) 2025-12-11
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
KR102406528B1 (ko) 2022-06-08
US11103463B2 (en) 2021-08-31
MX394249B (es) 2025-03-24
US20220016045A1 (en) 2022-01-20
KR20190034601A (ko) 2019-04-02
AU2023203618A1 (en) 2023-07-06
KR20220082928A (ko) 2022-06-17
CN116966166A (zh) 2023-10-31
JP2019523268A (ja) 2019-08-22
AU2017301928B2 (en) 2023-04-06
SG11201900692WA (en) 2019-02-27
AU2017301928A1 (en) 2019-02-14
CN109789106A (zh) 2019-05-21
KR102555208B1 (ko) 2023-07-17
CA3031945C (en) 2025-09-23
KR20190035801A (ko) 2019-04-03
CA3032044C (en) 2024-10-01
US20190247321A1 (en) 2019-08-15
CA3032148A1 (en) 2018-02-01
KR20230109782A (ko) 2023-07-20
JP7071330B2 (ja) 2022-05-18
WO2018022815A2 (en) 2018-02-01
RU2019105279A3 (enExample) 2020-12-23
CN109789105A (zh) 2019-05-21
MX2019001103A (es) 2019-09-27
JP2022121629A (ja) 2022-08-19
KR20220082929A (ko) 2022-06-17
US20180028462A1 (en) 2018-02-01
KR20190032512A (ko) 2019-03-27
RU2019105279A (ru) 2020-08-27
MX2022006681A (es) 2022-07-11
US10300025B2 (en) 2019-05-28
US20250325496A1 (en) 2025-10-23
US20180028512A1 (en) 2018-02-01
US20180028463A1 (en) 2018-02-01
AU2017302307A1 (en) 2019-02-14
WO2018022816A1 (en) 2018-02-01
JP2022093707A (ja) 2022-06-23
JP2019525932A (ja) 2019-09-12
US20190247320A1 (en) 2019-08-15
KR102406536B1 (ko) 2022-06-08
US20240156747A1 (en) 2024-05-16
US9993466B2 (en) 2018-06-12
CA3032044A1 (en) 2018-02-01
US10307379B2 (en) 2019-06-04
KR102406482B1 (ko) 2022-06-08
JP7251033B2 (ja) 2023-04-04
CN109789105B (zh) 2022-12-27
AU2023204240A1 (en) 2023-07-27
CA3031945A1 (en) 2018-02-01
EP3490558A1 (en) 2019-06-05
US20210015761A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CN109789105B (zh) 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
JP5658353B2 (ja) 経皮吸収製剤
WO2007094385A1 (ja) 凝集力向上及び徐放化の外用貼付剤
CA2951706A1 (en) Transdermal delivery system
JPH04217919A (ja) エペリゾンまたはトルペリゾン経皮吸収製剤
CN117157062B (zh) 抑制药物结晶的透皮贴剂及其制备方法
TW202317113A (zh) 使用經皮傳遞系統的組合療法處理
JPH06279288A (ja) パップ剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination